Synvisc perisynovitis

Pathology

Volumn 33, Issue 4, 2001, Pages 519-520

  Zardawi, Ibrahim M ^a   Chan, Ian ^b  

^a Newcastle Laboratory   (Australia)

^b Baringa Specialist Centre   (Australia)

Author keywords

Hyaluronan; Hylan G F 20; Synovitis; Synvisc

Indexed keywords

HYALURONIC ACID;

ADIPOSE TISSUE; ADULT; ARTICLE; CASE REPORT; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; GRANULOMATOUS INFLAMMATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; SYNOVITIS;

EID: 0035678113     PISSN: 00313025     EISSN: None     Source Type: Journal    
DOI: 10.1080/00313020120083296     Document Type: Article

References (7)

1. The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: A Canadian multicentre trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone
2. Viscosupplementation with hylan G-F 20: A 26 week controlled trial of efficacy and safety in the osteoarthritis joint
3. A risk-benefit assessment of injections of hyaluronan and its derivatives in the treatment of osteoarthritis of the knee
4. Acute local reaction after intra-articular hylan for osteoarthritis of the knee
5. Induction of an acute attack of calcium pyrophosphate dihydrate arthritis by intra-articular injection of hylan G-F 20 (Synvisc)
6. Importance of placement of intra-articular steroid injections
7. Acute local reaction after intra-articular hylan for osteoarthritis of the knee